This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

HomeDosingDosingRecommended dosingCYP3A4 coadministrationDosage modifications for adverse reactionsEfficacyAdjuvant treatment
of RCCPrimary EndpointAdvanced RCCPrimary EndpointSecondary EndpointsAdvanced pNETPrimary EndpointSecondary EndpointsImatinib-resistant or
-intolerant GISTPrimary EndpointSecondary EndpointsSafety ProfileAdjuvant treatment
of RCCImportant Safety InformationAdverse reactionsLab abnormalitiesDiscontinuation ratesAdvanced RCCImportant Safety InformationAdverse reactionsLab abnormalitiesDiscontinuation ratesAdvanced pNETImportant Safety InformationAdverse reactionsLab abnormalitiesDiscontinuation ratesImatinib-resistant or
-intolerant GISTImportant Safety InformationAdverse reactionsLab abnormalitiesDiscontinuation ratesPatient Support and Resources

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-SUT-USA-1033
You are now leaving PfizerYou are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. 

PP-SUT-USA-1020
INDICATIONS

SUTENT® (sunitinib malate) is indicated for:

  • the treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate
  • the treatment of adult patients with advanced renal cell carcinoma (RCC)
  • the adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy
  • the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease